Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Guodong Chen

Richard Y Huang

Alan J Korman

Mohan Srinivasan

Mark J Selby

Karla Ann Henning

Michelle Minhua Han

Haichun Huang

Nils Lonberg

Huiming Li

Indrani Chakraborty

Ekaterina G Deyanova

Paul O Sheppard

Aaron Paul Yamniuk

Christine Bee

Ginger Chao Rakestraw

Changyu Wang

Susan Wong

Bryan C Barnhart

Xiao Min Schebye

Achal Mukundrao Pashine

Shrikant Deshpande

Hong-An Truong

Richard Yu-Cheng Huang

Brigitte Devaux

Stanley Richard Krystek, Jr

Michelle Renee Kuhne

Ming Lei

Daniel F Ardourel

Andy X Deng

Sandra V Hatcher

Anan Chuntharapai

Liang Schweizer

Stephen Michael Carl

Maria N Jure-Kunkel

Martin J Corbett

John S Sack

Andrew Rankin

Lin Hui Su

Xiaodi Deng

Natalie Bezman

Joseph E Myers, Jr

Pingping Zhang

Joseph Toth

Emanuela Sega

Angela Goodenough

Scott R Presnell

Arvind Rajpal

Mark W Rixon

Josephine M Cardarelli

Alison Witte

Brenda L Stevens

Michael L Gosselin

Thomas D Kempe

Hui Wei

Vangipuram S Rangan

Lumelle A Schneeweis

Xiang Shao

Priyanka Apurva Madia

Susan Chien-Szu Wong

Amy D Jhatakia

Derek A Holmes

Dasa Lipovsek

Linda Liang

Xi-Tao Wang

Keith Sadoon Bahjat

Scott Ronald Brodeur

Robert J Johnston

Steven Sheriff

Irvith M Carvajal

Luis Borges

John P Throup

Christina Terragni

Qihong Zhao

Jason Robert Pinckney

Yun Wang

Alfred Robert Langish

Hong Shen

Diana Yuhui Chen

Steven R O'Neil

John Thomas Loffredo

Olufemi A Adelakun

Huadong Sun

Cristian Rodriguez

Rose A Dibella

Anne C Lewin

David A Critton

Pavel Strop

Robert F Graziano

Akbar Nayeem

Li-Sheng Lu

Michael Quigley

Jun Zhang

Hadia Lemar

Hong-An Troung

Michelle Kuhne

Yiming Yin

Peter Sung Keun Lee

Gamze Ozlem Camdere

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to ILT4

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to vista at acidic pH

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Nucleic acids encoding anti-TREM-1 antibodies

Anti-TREM-1 antibodies and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Antibodies against IL-7R alpha subunit and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

TL1A antibodies and methods of treatment

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

IP-10 antibodies and their uses

Growing community of inventors

East Brunswick, NJ, United States of America

Guodong Chen